Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from RCUS

This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

The Insider Report: Prepare for the Next Dip Buying Opportunity

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Is Arcus Biosciences Stock Trading Higher On Monday?

In the relentless quest for groundbreaking cancer therapies, innovative drug trials are reshaping treatment landscapes and redefining patient hope. Arcus Biosciences Inc. (NYSE:RCUS) on Monday announced new monotherapy data for casdatifan in late-line metastatic clear cell renal cell carcinoma (ccRCC).

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. (NYSE:UEC), saying, “I like nuclear.”

Top 3 Biotech Picks for Profits and Value

The biotechnology industry thrives with innovation, along with the pharmacy market's expansion powered by digitalization. Hence, it might be ideal to buy fundamentally solid biotech stocks Merck KGaA (MKKGY), Entrada Therapeutics (TRDA), and Gilead Sciences (GILD) for profits and value. Read more to find out….

Top 4 Biotech Stock Buys for 2024 Gains

The biotech industry's dynamic growth, spurred by government backing and technological advances, addresses rising disease challenges and propels advancements in healthcare. Hence, fundamentally strong biotech stocks Gilead Sciences (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be solid investments for upcoming year gains. Read more….

inkl

Read news from The Economist, FT, and more,
with one subscription

2 Game-Changing Biotech Stocks, 1 to Sell Now

2 Game-Changing Biotech Stocks, 1 to Sell Now

As the biotech industry looks well-positioned for solid growth driven by strong government support and a growing foothold of personalized medicines, it could be wise for investors to buy fundamentally strong biotech stocks Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN). However, fundamentally weak Titan Pharmaceuticals (TTNP) might be best avoided.…

Arcus Biosciences Earnings Perspective: Return On Capital Employed

Arcus Biosciences Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Arcus Biosciences (NYSE:RCUS) reported Q1 sales of $18.00 million. Earnings fell to a loss of $67.99 million, resulting in a 124.34% decrease from last quarter.

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

Arcus Biosciences's Earnings Outlook

Arcus Biosciences's Earnings Outlook

Arcus Biosciences (NYSE:RCUS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Arcus Biosciences will report an earnings per share (EPS) of $-0.31.

Recap: Arcus Biosciences Q4 Earnings

Recap: Arcus Biosciences Q4 Earnings

Arcus Biosciences (NYSE:RCUS) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:10 PM. Here's what investors need to know about the announcement.

Arcus Biosciences's Earnings: A Preview

Arcus Biosciences's Earnings: A Preview

Arcus Biosciences (NYSE:RCUS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts estimate that Arcus Biosciences will report an earnings per share (EPS) of $-0.74.

1

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Gilead Sciences Inc

Regeneron Pharmaceuticals Inc

Jazz Pharmaceuticals plc

Incyte Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

404,112 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play